4-AP挑战揭示了布里瓦拉塞坦早期干预可以防止老鼠的创伤后发病
Ana Mejia-Bautista1, Hillary B Michelson1, Anika Sanjana1
1Department of Physiology and Pharmacology, SUNY Downstate Health Sciences University, 450 Clarkson Ave, Brooklyn, NY 11203, USA; Program in Neural and Behaviroal Science, SUNY Downstate Health Sciences University, 450 Clarkson Ave, Brooklyn, NY 11203, USA; Robert F. Furchgott Center for Behavioral and Neural Science, SUNY Downstate Health Sciences University, 450 Clarkson Ave, Brooklyn, NY 11203, USA.
Epilepsy research
|August 24, 2023
概括
在创伤性脑损伤 (TBI) 后早期给大鼠服用布里瓦拉 (BRV) 显著降低了发作易感性. 这一发现支持BRV作为创伤后 (PTE) 的潜在预防治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 的研究研究.
- 创伤性脑损伤 (TBI) 模型
背景情况:
- 创伤后 (PTE) 缺乏有效的临床预防治疗.
- 以前的研究表明,莱维拉 (LEV) 和布里瓦拉 (BRV) 在预防大鼠神经创伤后的型活动方面具有有效性.
- 动物TBI模型通常需要化学药来评估由于自发性发病率低而导致的发病易感性.
研究的目的:
- 调查布里瓦拉 (BRV) 作为控制皮质冲击 (CCI) 损伤后的抗性治疗的疗效.
- 为了利用低剂量的4-aminopyridine (4-AP) 化学挑战来评估老鼠TBI模型中的创伤后发.
主要方法:
- 在Sprague-Dawley大鼠 (P24-35) 中引发了严重的CCI损伤.
- 组分别在受伤后0-2分钟或30分钟接受BRV (21毫克/千克或100毫克/千克).
- 伤害后四到八周,使用低剂量的4-aminopyridine (4-AP) 评估了发作易感性,并对4/5阶段的发作进行监测.
主要成果:
- 与模拟受伤对照相比,CCI损伤在4-8周内显著增加了4-AP的发作易感性,增加了两倍.
- 在TBI后30分钟内服用单剂量BRV有效降低了受伤诱导的发作易感性.
- BRV治疗使CCI大鼠中引起发作的比例正常化,与控制水平相比.
结论:
- 这项研究引入了低剂量4-AP化学挑战,用于评估CCI后两个月内在老鼠中的发性.
- 在TBI后30分钟内一次的BRV剂量有效地预防了发作易感性的增加.
- 早期的BRV干预在预防创伤后 (PTE) 方面显示出有前途.
相关概念视频
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
344
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
344
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
460
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
460
01:24Arteries of the Lower Limbs
213
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
213